Lucio N. Gordan

Dr. Lucio N. Gordan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
LGLucio N. Gordan
Lucio N. Gordan
CTCarlyn Rose Tan
Carlyn Rose Tan
RVRobert Vescio
Robert Vescio
JYJing Christine Ye
Jing Christine Ye
CSCarolina Schinke
Carolina Schinke
SUSaad Z. Usmani
Saad Z. Usmani
Daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are preferred regimens for transplant ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Both DRd and VRd demonstrated superior efficacy versus Rd in the MAIA and SWOG S0777 trials, respectively, but there is no head-to-head (H2H) clinical trial comparing their efficacy. Differing populations in the MAIA and S0777 trials make an unadjusted comparison of outcomes challenging and biased. The current TAURUS study is the first real-world H2H study comparing progression-free survival (PFS) among TIE NDMM patients treated with DRd or VRd as first-line (1L) in similar clinical settings. A multicenter chart review study was conducted at nine sites across the United States. All TIE patients treated with DRd and a randomly selected population of VRd patients were included. TIE NDMM patients aged ≥65 were included if they initiated 1L DRd/VRd between January 2019 and September 2021. PFS was defined as the time from DRd/VRd initiation until disease progression or death. A doubly-robust multivariable Cox regression model combined with inverse probability of treatment weighting (IPTW) methodology was used to compare PFS between cohorts. Weighted cohorts comprised 91 DRd and 87 VRd patients. Thirteen DRd and 24 VRd patients experienced progression/death. Patients treated with DRd had a lower risk of progression/death versus VRd (adjusted hazard ratio: 0.35, 95% confidence interval: [0.17; 0.73]). DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.

1 March 2019
Verified
Journal Article
Closed access
LGLucio N. Gordan
Lucio N. Gordan
MBMarlo Blazer
Marlo Blazer
VSVishal Saundankar
Vishal Saundankar
DKDenise Kazzaz
Denise Kazzaz
SWSusan Weidner
Susan Weidner
MEMichael Eaddy
Michael Eaddy

1 December 2020 in The American Journal of Managed Care
Verified
Journal Article
Closed access
LGLucio N. Gordan
Lucio N. Gordan
SWSusan Weidner
Susan Weidner
The COVID-19 pandemic has impacted specialty practices generally and oncology practices especially have been resilient throughout the pandemic.

14 January 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
LGLucio N. Gordan
Lucio N. Gordan
DRDavid Ray
David Ray
SIStephen Ijioma
Stephen Ijioma
George DranitsarisGeorge Dranitsaris
George Dranitsaris
AWAmanda K Warner
Amanda K Warner
SPShachar Peles
Shachar Peles
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program in patients with relapsed/refractory multiple myeloma (RRMM) receiving selinexor. Features of the BP program that were specific to selinexor were initiating selinexor at doses ≤80 mg once weekly and the upfront use of standardized antiemetics. Study endpoints included time to treatment failure (TTF), duration of therapy, dose limiting toxicities and overall survival. Comparative analysis on TTF and duration of therapy was conducted using a log-rank test and multivariate Cox proportional hazard regression. Over the ensuing 12-month post-BP period, 41 patients received selinexor-based therapy compared to 68 patients who received selinexor-based therapy pre-BP implementation. Patients treated in the post-BP period had reductions in TTF (hazard ratio [HR] = 0.50; 95% CI: 0.27 to 0.92). Patients in the pre-BP period were four times more likely to stop therapy than those in the post-period (odds ratio [OR] = 4.0, 95% CI: 1.75 to 9.3). The findings suggest a BP program tailored to selinexor could increase the time to treatment failure, increase treatment duration and lower the incidence of drug limiting toxicities.

20 August 2025 in Future Oncology
Verified
Journal Article
Open access
LGLucio N. Gordan
Lucio N. Gordan
AWAmanda Warner
Amanda Warner
THTrevor Heritage
Trevor Heritage
AMAmy Ming
Amy Ming
NGNiodita Gupta-Werner
Niodita Gupta-Werner
ACAnnelore Cortoos
Annelore Cortoos
To explore community hematologist/oncologist perspectives on the patterns, drivers, and barriers of use of minimal residual disease (MRD) testing in patients with multiple myeloma (MM), and gain understanding on the use of these test results in clinical decision-making and response-adapted treatment approaches. A survey was conducted among hematologists/oncologists from a large community oncology practice network in the US who use MRD testing in the management of patients with MM. Of 22 hematologists/oncologists included, 72.7% reported being comfortable/very comfortable with MRD testing but prescribed a median of only 2.5 tests between September 2019 and October 2023. The most frequently reported driver for MRD testing was to monitor patient remission status. The logistics of sending samples to MRD testing facilities was the most frequently reported perceived barrier for MRD testing. The use of MRD test results to guide treatment decisions and further MRD monitoring varied. There are opportunities to reduce the barriers for the use of MRD testing and for generation of additional data on the clinical impact of these test results to support the development of guidelines and provide further education on the implementation of MRD test results in clinical practice and aid clinical decision-making.

1 October 2018
Verified
Journal Article
Closed access
LGLucio N. Gordan
Lucio N. Gordan
DPDebra Patt
Debra Patt